Cargando…
Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci
The genus Enterococcus comprises a ubiquitous group of Gram-positive bacteria that can cause diverse health care-associated infections. Their genome plasticity enables easy acquisition of virulence factors as well as antibiotic resistances. Urinary tract infections (UTIs) and catheter-associated UTI...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558097/ https://www.ncbi.nlm.nih.gov/pubmed/32887311 http://dx.doi.org/10.3390/antibiotics9090567 |
_version_ | 1783594563970007040 |
---|---|
author | Montalbán-López, Manuel Cebrián, Rubén Galera, Rosa Mingorance, Lidia Martín-Platero, Antonio M. Valdivia, Eva Martínez-Bueno, Manuel Maqueda, Mercedes |
author_facet | Montalbán-López, Manuel Cebrián, Rubén Galera, Rosa Mingorance, Lidia Martín-Platero, Antonio M. Valdivia, Eva Martínez-Bueno, Manuel Maqueda, Mercedes |
author_sort | Montalbán-López, Manuel |
collection | PubMed |
description | The genus Enterococcus comprises a ubiquitous group of Gram-positive bacteria that can cause diverse health care-associated infections. Their genome plasticity enables easy acquisition of virulence factors as well as antibiotic resistances. Urinary tract infections (UTIs) and catheter-associated UTIs are common diseases caused by enterococci. In this study, Enterococcus strains isolated from UTIs were characterized, showing that the majority were E. faecalis and contained several virulence factors associated to a better colonization of the urinary tract. Their susceptibility against the bacteriocin AS-48 and several antibiotics was tested. AS-48 is a potent circular bacteriocin that causes bacterial death by pore formation in the cell membrane. The interest of this bacteriocin is based on the potent inhibitory activity, the high stability against environmental conditions, and the low toxicity. AS-48 was active at concentrations below 10 mg/L even against antibiotic-resistant strains, whereas these strains showed resistance to, at least, seven of the 20 antibiotics tested. Moreover, the effect of AS-48 combined with antibiotics commonly used to treat UTIs was largely synergistic (with up to 100-fold MIC reduction) and only occasionally additive. These data suggest AS-48 as a potential novel drug to deal with or prevent enterococcal infections. |
format | Online Article Text |
id | pubmed-7558097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75580972020-10-22 Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci Montalbán-López, Manuel Cebrián, Rubén Galera, Rosa Mingorance, Lidia Martín-Platero, Antonio M. Valdivia, Eva Martínez-Bueno, Manuel Maqueda, Mercedes Antibiotics (Basel) Article The genus Enterococcus comprises a ubiquitous group of Gram-positive bacteria that can cause diverse health care-associated infections. Their genome plasticity enables easy acquisition of virulence factors as well as antibiotic resistances. Urinary tract infections (UTIs) and catheter-associated UTIs are common diseases caused by enterococci. In this study, Enterococcus strains isolated from UTIs were characterized, showing that the majority were E. faecalis and contained several virulence factors associated to a better colonization of the urinary tract. Their susceptibility against the bacteriocin AS-48 and several antibiotics was tested. AS-48 is a potent circular bacteriocin that causes bacterial death by pore formation in the cell membrane. The interest of this bacteriocin is based on the potent inhibitory activity, the high stability against environmental conditions, and the low toxicity. AS-48 was active at concentrations below 10 mg/L even against antibiotic-resistant strains, whereas these strains showed resistance to, at least, seven of the 20 antibiotics tested. Moreover, the effect of AS-48 combined with antibiotics commonly used to treat UTIs was largely synergistic (with up to 100-fold MIC reduction) and only occasionally additive. These data suggest AS-48 as a potential novel drug to deal with or prevent enterococcal infections. MDPI 2020-09-02 /pmc/articles/PMC7558097/ /pubmed/32887311 http://dx.doi.org/10.3390/antibiotics9090567 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Montalbán-López, Manuel Cebrián, Rubén Galera, Rosa Mingorance, Lidia Martín-Platero, Antonio M. Valdivia, Eva Martínez-Bueno, Manuel Maqueda, Mercedes Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci |
title | Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci |
title_full | Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci |
title_fullStr | Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci |
title_full_unstemmed | Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci |
title_short | Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci |
title_sort | synergy of the bacteriocin as-48 and antibiotics against uropathogenic enterococci |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7558097/ https://www.ncbi.nlm.nih.gov/pubmed/32887311 http://dx.doi.org/10.3390/antibiotics9090567 |
work_keys_str_mv | AT montalbanlopezmanuel synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci AT cebrianruben synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci AT galerarosa synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci AT mingorancelidia synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci AT martinplateroantoniom synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci AT valdiviaeva synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci AT martinezbuenomanuel synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci AT maquedamercedes synergyofthebacteriocinas48andantibioticsagainsturopathogenicenterococci |